These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1283 related articles for article (PubMed ID: 28476146)

  • 21. Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients.
    Parajuli DR; Shakib S; Eng-Frost J; McKinnon RA; Caughey GE; Whitehead D
    BMC Cardiovasc Disord; 2021 Feb; 21(1):104. PubMed ID: 33602125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey.
    Komajda M; Anker SD; Cowie MR; Filippatos GS; Mengelle B; Ponikowski P; Tavazzi L;
    Eur J Heart Fail; 2016 May; 18(5):514-22. PubMed ID: 27095461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy modifications during hospitalization in patients with chronic heart failure.
    Detiček A; Locatelli I; Roblek T; Mrhar A; Lainscak M
    Eur J Intern Med; 2016 Apr; 29():52-8. PubMed ID: 26775137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Individual Patient Profiles on Adherence to Guideline Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction: VCOR-HF Study.
    Driscoll A; Dinh D; Wong J; Hopper I; Mariani J; Zimmet H; Brennan A; Lefkovits J; Carruthers H; Reid CM
    Heart Lung Circ; 2020 Dec; 29(12):1782-1789. PubMed ID: 32646638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence to ESC guideline-recommended medications over a 36-month follow-up period after hospitalization for heart failure: Results from the EPICAL2 cohort study.
    Bitar S; Agrinier N; Alla F; Rossignol P; Mebazaa A; Thilly N
    Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1489-1500. PubMed ID: 31339629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015.
    Kruik-Kollöffel WJ; Linssen GCM; Kruik HJ; Movig KLL; Heintjes EM; van der Palen J
    Heart Fail Rev; 2019 Jul; 24(4):499-510. PubMed ID: 30848404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population.
    Jonsson A; Norberg H; Bergdahl E; Lindmark K
    Cardiovasc Ther; 2018 Oct; 36(5):e12459. PubMed ID: 30019390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
    Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
    Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
    Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of predictive modeling in implementing optimal heart failure therapy.
    Prasad H; Sra J; Levy WC; Stapleton DD
    Am J Med Sci; 2011 Mar; 341(3):185-90. PubMed ID: 21233695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A tool for assessment of heart failure prescribing quality: A systematic review and meta-analysis.
    El Hadidi S; Darweesh E; Byrne S; Bermingham M
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):685-694. PubMed ID: 29659109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry.
    Khazanie P; Liang L; Curtis LH; Butler J; Eapen ZJ; Heidenreich PA; Bhatt DL; Peterson ED; Yancy CW; Fonarow GC; Hernandez AF
    Circ Heart Fail; 2016 Feb; 9(2):e002444. PubMed ID: 26867758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of guideline-recommended versus non-guideline-recommended β-blocker and Doppler echocardiographic parameters on 1-year mortality in Thai ischemic cardiomyopathy patients: A prospective multicenter registry.
    Wongpraparut N; Siwamogsatham S; Thongsri T; Ngamjanyaporn P; Phrommintikul A; Jirajarus K; Tangcharoen T; Bhumimuang K; Kaewsuwanna P; Krittayaphong R; Pongakasira R; White HD
    BMC Cardiovasc Disord; 2020 Jan; 20(1):8. PubMed ID: 31918676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures.
    Allen LA; Fonarow GC; Liang L; Schulte PJ; Masoudi FA; Rumsfeld JS; Ho PM; Eapen ZJ; Hernandez AF; Heidenreich PA; Bhatt DL; Peterson ED; Krumholz HM;
    Circulation; 2015 Oct; 132(14):1347-53. PubMed ID: 26316616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of the MAT-CHDSP to assess guideline adherence and therapy goal achievement in secondary prevention of coronary heart disease after percutaneous coronary intervention.
    Garcia BH; Småbrekke L; Trovik T; Giverhaug T
    Eur J Clin Pharmacol; 2013 Mar; 69(3):703-9. PubMed ID: 22990329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction.
    Butler J; Yang M; Manzi MA; Hess GP; Patel MJ; Rhodes T; Givertz MM
    J Am Coll Cardiol; 2019 Mar; 73(8):935-944. PubMed ID: 30819362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attainment of Guideline-Directed Medical Treatment in Stable Ischemic Heart Disease Patients With and Without Chronic Kidney Disease.
    Koutroumpakis E; Gosmanova EO; Stahura H; Jou S; Alreshq R; Ata A; Sidhu MS; Philbin E; Boden WE; Lyubarova R
    Cardiovasc Drugs Ther; 2019 Aug; 33(4):443-451. PubMed ID: 31123935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
    Vaduganathan M; Fonarow GC; Greene SJ; DeVore AD; Kavati A; Sikirica S; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
    JACC Heart Fail; 2020 Jun; 8(6):469-480. PubMed ID: 32387066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Keil U;
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):121-37. PubMed ID: 19287307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.